ARIAD strength attributed to inclusion on EMA meeting agenda

December 17, 2013

The European Medicines Agency will review Ariad's Iclusig at its December meeting, according to a meeting agenda posted to the regulator's website. Ariad shares are up 9.8% to $4.24 following circulation of the agenda.